Shares of genomics company Illumina (NASDAQ:ILMN) fell 3.6% in the afternoon session after the major indices pulled back ...

Combining SomaLogic's proteomics technology with Illumina's scalable NGS ecosystem, DRAGEN™ software, and Illumina Connected Multiomics will accelerate the technology development roadmap for ...

SAN DIEGO, June 25, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced it has entered into a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire ...

Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market ...

Looking forward, we believe optionality from new tests other companies run using Illumina products, particularly for cancer screening and detection, should create a long-term growth tailwind.

Illumina faces significant challenges, including revenue declines, margin pressures, and geopolitical hurdles. Read how ILMN stock fits in a barbell portfolio.

Illumina slashes costs by $100 million after China bans its sequencers. The company lowers its 2025 EPS outlook and aims for high-single-digit growth by 2027.

Illumina is reducing its forecast for this year’s financial performance and cutting $100 million in spending because China barred sales of the company’s gene-sequencing machines.

Brown Advisors, an investment management company, released its “Brown Advisors Global Leaders Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here.

Illumina's High-Sensitivity WGS Technology in Blood Cancer Diagnostics Shows 100% Sensitivity, Poised to Revolutionize Testing Despite Market Adoption Barriers ...

Illumina just demonstrated its WGS effectiveness in blood cancer diagnostics. The research showed that Illumina's WGS workflow achieving 100% sensitivity in finding rare mutations in Acute Myeloid ...

Illumina’s success depends on management’s ability to astutely allocate capital to maintain its top-tier position in the sequencing market, which is not guaranteed.